Buprenex, Suboxone(buprenorphine)
Belbuca, Brixadi, Buprenorphine, Butrans, Buvidal, Sixmo, Sublocade, Suboxone, Zubsolv (buprenorphine) is a small molecule pharmaceutical. Buprenorphine was first approved as Buprenex on 1982-01-01. It is used to treat heroin dependence and pain in the USA. It has been approved in Europe to treat opioid-related disorders. The pharmaceutical is active against mu-type opioid receptor and kappa-type opioid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Belbuca, Buprenorphine, Butrans, Sublocade (discontinued: Buprenex, Buprenorphine, Probuphine, Subutex)
CombinationsBuprenorphine naloxone, Suboxone, Zubsolv (discontinued: Bunavail, Buprenorphine naloxone, Cassipa, Suboxone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Buprenorphine hydrochloride
+
Naloxone hydrochloride
Buprenorphine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SUBLOCADE | Indivior | N-209819 RX | 2017-11-30 | 2 products, RLD, RS |
| BUTRANS | Purdue Pharma | N-021306 RX | 2010-06-30 | 5 products, RLD, RS |
Buprenorphine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BELBUCA | BioDelivery Sciences | N-207932 RX | 2015-10-23 | 7 products, RLD, RS |
Show 3 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| belbuca | New Drug Application | 2023-12-21 |
| brixadi | New Drug Application | 2023-12-28 |
| buprenophine and naloxone | ANDA | 2016-09-27 |
| buprenorphine | ANDA | 2024-12-30 |
| buprenorphine and naloxone | ANDA | 2024-11-20 |
| buprenorphine hcl | ANDA | 2024-10-07 |
| buprenorphine hcl and naloxone hcl | ANDA | 2024-05-20 |
| buprenorphine hydrochloride | ANDA | 2025-01-06 |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | ANDA | 2025-01-13 |
| buprenorphine hydrochloride sublingual | ANDA | 2017-09-15 |
Show 7 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
BUPRENORPHINE, BRIXADI, BRAEBURN | |||
| 2026-05-23 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Buprenorphine, Sublocade, Indivior | |||
| 10646484 | 2038-06-22 | U-2489 | |
| 11000520 | 2035-11-06 | U-3111 | |
| 11839611 | 2035-11-06 | U-3111 | |
| 8921387 | 2032-01-06 | DP | U-2173, U-2174 |
| 8975270 | 2031-09-05 | DP | U-2175, U-2206 |
| 10558394 | 2031-06-25 | DP | |
| 9272044 | 2031-06-06 | U-2176, U-2177, U-2178, U-2209 | |
| 9498432 | 2031-06-06 | DP | U-2179 |
| 9782402 | 2031-06-06 | DP | U-2176, U-2180, U-2207, U-2208 |
| 9827241 | 2031-06-06 | DP | U-2174, U-2181, U-2206, U-2210, U-2211 |
| 10198218 | 2031-06-06 | U-2489 | |
| 10592168 | 2031-06-06 | U-2489 | |
| Buprenorphine Hydrochloride / Naloxone Hydrochloride, Bunavail, Bdsi | |||
| 9522188 | 2035-04-24 | DP | |
| 8703177 | 2032-08-20 | DP | |
| Buprenorphine Hydrochloride, Belbuca, Bdsi | |||
| 9901539 | 2032-12-21 | U-1556 | |
| 8147866 | 2027-07-23 | DP | U-1521, U-1769 |
| 9655843 | 2027-07-23 | DP | U-1556, U-2017 |
| Buprenorphine Hydrochloride / Naloxone Hydrochloride, Zubsolv, Orexo Us Inc | |||
| 8940330 | 2032-09-18 | DP | |
| 9259421 | 2032-09-18 | DP | |
| 9439900 | 2032-09-18 | DP | |
| 10874661 | 2032-09-18 | DP | |
| 10946010 | 2032-09-18 | DP | |
| 11020387 | 2032-09-18 | DP | U-3131 |
| 11020388 | 2032-09-18 | DP | U-3131 |
| 11433066 | 2032-09-18 | U-3131 | |
| 8470361 | 2030-05-22 | DP | U-1425 |
| 8658198 | 2027-12-03 | DP | U-1494 |
| Buprenorphine, Brixadi, Braeburn | |||
| 9937164 | 2032-07-26 | DP | U-3618 |
| 10912772 | 2032-07-26 | U-3617 | |
| 11110084 | 2032-07-26 | DP | U-3616 |
| 11135215 | 2032-07-26 | DP | |
| 8236292 | 2027-01-10 | DP | U-3619 |
| 8236755 | 2026-07-31 | DP | U-3620 |
| 8545832 | 2025-06-06 | DP | U-3619 |
| Buprenorphine Hydrochloride / Naloxone Hydrochloride, Suboxone, Indivior | |||
| 8475832 | 2030-03-26 | DP | U-1411 |
| 9687454 | 2029-08-07 | DP | U-1464 |
| 11135216 | 2029-08-07 | DP | U-3111 |
| 8603514 | 2024-04-03 | DP | U-1464 |
| Buprenorphine Hydrochloride, Probuphine, Titan Pharms | |||
| 7736665 | 2024-04-25 | U-1878 | |
ATC Codes
N: Nervous system drugs
— N02: Analgesics
— N02A: Opioid analgesics
— N02AE: Oripavine derivatives analgesics
— N02AE01: Buprenorphine
— N07: Other nervous system drugs in atc
— N07B: Drugs used in addictive disorders
— N07BC: Drugs used in opioid dependence
— N07BC01: Buprenorphine
— N07BC51: Buprenorphine, combinations
HCPCS
Code | Description |
|---|---|
| G2068 | Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) |
| G2069 | Medication assisted treatment, buprenorphine (injectable); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) |
| G2070 | Medication assisted treatment, buprenorphine (implant insertion); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) |
| G2071 | Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) |
| G2072 | Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) |
| G2079 | Take-home supply of buprenorphine (oral); up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure |
| J0570 | Buprenorphine implant, 74.2 mg |
| J0571 | Buprenorphine, oral, 1 mg |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine |
| J0573 | Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine |
Show 5 more
Clinical
Clinical Trials
729 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 5 | 7 | 3 | 9 | 9 | 33 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 2 | — | 1 | 3 | 5 | 11 |
| Hepatitis c | D006526 | — | B19.2 | — | — | — | 2 | — | 2 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | — | — | 2 | — | 2 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | — | — | 2 | — | 2 |
| Liver failure | D017093 | HP_0001399 | K72.9 | — | — | — | 1 | — | 1 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | — | 1 | — | 1 |
| Hepatic insufficiency | D048550 | — | — | — | — | — | 1 | — | 1 |
| Hepatic encephalopathy | D006501 | — | K72.91 | — | — | — | 1 | — | 1 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heroin dependence | D006556 | EFO_0004240 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Opiate overdose | D000083682 | — | — | — | — | — | — | 1 | 1 |
| Drug overdose | D062787 | — | — | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Buprenorphine |
| INN | buprenorphine |
| Description | Buprenorphine is a morphinane alkaloid that is 7,8-dihydromorphine 6-O-methyl ether in which positions 6 and 14 are joined by a -CH2CH2- bridge, one of the hydrogens of the N-methyl group is substituted by cyclopropyl, and a hydrogen at position 7 is substituted by a 2-hydroxy-3,3-dimethylbutan-2-yl group. It is highly effective for the treatment of opioid use disorder and is also increasingly being used in the treatment of chronic pain. It has a role as an opioid analgesic, a mu-opioid receptor agonist, a delta-opioid receptor antagonist and a kappa-opioid receptor antagonist. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5 |
Identifiers
| PDB | — |
| CAS-ID | 52485-79-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL511142 |
| ChEBI ID | — |
| PubChem CID | 644073 |
| DrugBank | DB00921 |
| UNII ID | 40D3SCR4GZ (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Belbuca – BioDelivery Sciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Belbuca – Collegium Pharmaceutical
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Bunavail – BioDelivery Sciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Buprenorphine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Buprenorphine
+
Naloxone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 46,334 documents
View more details
Safety
Black-box Warning
Black-box warning for: Belbuca, Brixadi, Buprenorphine transdermal system, Butrans, Sublocade
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
122,486 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use